Zai Lab Ltd.

As of June 30, 2026, Zai Lab Ltd. carries a market capitalization of 16.23B, placing it among publicly traded companies globally. Its enterprise value stands at 13.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zai Lab Ltd.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Zai Lab Ltd. has 1.12B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.54, and the price-to-book ratio stands at 3.41.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.38B versus a market cap of 16.23B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zai Lab Ltd. maintains a current ratio of 2.13, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.94, indicating elevated leverage, while an interest coverage ratio of -41.46 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zai Lab Ltd. posted a negative return on equity (ROE) of -26.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.81, reflecting losses generated across the asset base. The company generates approximately 1.95M in revenue per employee across its workforce of 1,805.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.57 indicates how many times Zai Lab Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zai Lab Ltd. recorded an income tax benefit of -19.67M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.50B and -1.48B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Zai Lab Ltd.'s stock has declined approximately 18.44% over the past 52 weeks. The 50-day moving average sits at 19.77, while the 200-day moving average is 16.16.

Over the twelve months ended June 30, 2026, Zai Lab Ltd. generated 3.53B in revenue and converted that into -1.48B in net income, yielding earnings per share of -1.33. EBITDA reached -1.95B, while operating income came in at -2.05B.

As of June 30, 2026, Zai Lab Ltd. holds 4.84B in cash and equivalents against 2.00B in total debt, resulting in a net debt position of -2.90B. Total book value stands at 4.76B, with working capital of 3.81B providing operational flexibility.

Zai Lab Ltd. produced -1.05B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -228.45M in capital expenditures, free cash flow totaled -1.27B - equivalent to -1.15 per share.

Over the twelve months ended June 30, 2026, Zai Lab Ltd. posted a gross margin of 56.47, reflecting its pricing power and cost economics. The operating margin of -58.27 and net profit margin of -41.86 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.16, meaning Zai Lab Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Zai Lab Ltd.'s most recent stock split took place on April 14, 2022 with a 1:10 split ratio.

As of June 30, 2026, Zai Lab Ltd. has an Altman Z-Score of -1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.